Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 11/20 | 0.39 |
| ▸ | F13A1 | P00488 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TGM1 | P22735 | 1/20 | 0.37 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | GSTO1 | P78417 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL5242393 | 0.73 | TGM2 (0.37) | TGM2F13A1LMNATGM1TGM3 | |
| Sulfuric Acid SCHEMBL4458775 | 0.72 | EGFR (0.41) | TGM2EGFR | |
| SCHEMBL20379487 | 0.67 | TGM2 (0.50) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL5553620 | 0.67 | TGM2 (0.50) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL4452979 | 0.66 | TGM2 (0.46) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL31043510 | 0.65 | TGM2 (0.42) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL26026744 | 0.65 | TGM2 (0.48) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL13703362 | 0.64 | TGM2 (0.37) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL18010044 | 0.62 | TGM2 (0.41) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL11331053 | 0.62 | TGM2 (0.53) | TGM2F13A1LMNATGM1TGM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023201315-A2 | OPHTHALMIC AGENT IN PRESERVATIVE REMOVAL DEVICE | TearClear Corp. (US) | 2023-10-19 | — | — | WO | claimed |
| CN-116322597-A | Systems and methods for preservative removal in ophthalmic formulations | 特清公司 | 2023-06-23 | — | — | CN | claimed |
| EP-4192405-A1 | SYSTEMS AND METHODS FOR PRESERVATIVE REMOVAL FROM OPHTHALMIC FORMULATIONS | Tearclear Corp. (US) | 2023-06-14 | — | — | EP | claimed |
| US-11478378-B2 | Systems and methods for preservative removal from ophthalmic formulations | TearClear Corp. (US) | 2022-10-25 | — | — | US | claimed |
| WO-2022031841-A1 | SYSTEMS AND METHODS FOR PRESERVATIVE REMOVAL FROM OPHTHALMIC FORMULATIONS | TearClear Corp. (US) | 2022-02-10 | — | — | WO | claimed |
| US-20220039997-A1 | SYSTEMS AND METHODS FOR PRESERVATIVE REMOVAL FROM OPHTHALMIC FORMULATIONS | TearClear Corp. | 2022-02-10 | — | — | US | claimed |
| US-20210393481-A1 | SYSTEMS AND METHODS FOR PRESERVATIVE REMOVAL FROM OPHTHALMIC FORMULATIONS COMPRISING COMPLEXING AGENTS | TearClear Corp. | 2021-12-23 | — | — | US | claimed |
| EP-3920988-A1 | SYSTEMS AND METHODS FOR PRESERVATIVE REMOVAL FROM OPHTHALMIC FORMULATIONS COMPRISING COMPLEXING AGENTS | Tearclear Corp. (US) | 2021-12-15 | — | — | EP | claimed |
| WO-2020163528-A1 | SYSTEMS AND METHODS FOR PRESERVATIVE REMOVAL FROM OPHTHALMIC FORMULATIONS COMPRISING COMPLEXING AGENTS | TearClear Corp. (US) | 2020-08-13 | — | — | WO | claimed |
| US-20200246222-A1 | Systems and Methods for Preservative Removal from Ophthalmic Formulations Comprising Complexing Agents | TearClear Corp. | 2020-08-06 | — | — | US | claimed |
| EP-3946183-B1 | A FLOW CONTROL DEVICE FOR DELIVERING AN OPHTHALMIC FORMULATION | TEARCLEAR CORP (US) | 2025-10-29 | — | — | EP | disclosed |
| CN-119462999-A | Ureido-functionalized imidazole polyionic liquid and preparation method and application thereof | 浙江理工大学嵊州创新研究院有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-11963906-B2 | Devices and methods for flow control of ophthalmic formulations | TearClear Corp. (US) | 2024-04-23 | — | — | US | disclosed |
| WO-2023201315-A2 | OPHTHALMIC AGENT IN PRESERVATIVE REMOVAL DEVICE | TearClear Corp. (US) | 2023-10-19 | — | — | WO | disclosed |
| US-20230263659-A1 | DEVICES AND METHODS FOR FLOW CONTROL OF OPHTHALMIC FORMULATIONS | TearClear Corp. | 2023-08-24 | — | — | US | disclosed |
| EP-3920988-A1 | SYSTEMS AND METHODS FOR PRESERVATIVE REMOVAL FROM OPHTHALMIC FORMULATIONS COMPRISING COMPLEXING AGENTS | Tearclear Corp. (US) | 2021-12-15 | — | — | EP | disclosed |
| US-20200337895-A1 | DEVICE AND METHODS FOR FLOW CONTROL OF OPHTHALMIC FORMULATIONS | GILERO, LLC (DBA EG-GILERO) | 2020-10-29 | — | — | US | disclosed |
| WO-2020198655-A1 | DEVICES AND METHODS FOR FLOW CONTROL OF OPHTHALMIC FORMULATIONS | TearClear Corp. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020163528-A1 | SYSTEMS AND METHODS FOR PRESERVATIVE REMOVAL FROM OPHTHALMIC FORMULATIONS COMPRISING COMPLEXING AGENTS | TearClear Corp. (US) | 2020-08-13 | — | — | WO | disclosed |
| US-20200246222-A1 | Systems and Methods for Preservative Removal from Ophthalmic Formulations Comprising Complexing Agents | TearClear Corp. | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246222-A1 | Systems and Methods for Preservative Removal from Ophthalmic Formulations Comprising Complexing Agents | SMURF1, CRYAA, PON1 | TGM2 4638/4885F13A1 165/4885LMNA 8/4885 |
| US-20210393481-A1 | SYSTEMS AND METHODS FOR PRESERVATIVE REMOVAL FROM OPHTHALMIC FORMULATIONS COMPRISING COMPLEXING AGENTS | SMURF1, CRYAA, PON1 | TGM2 4638/4885F13A1 165/4885LMNA 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.